# Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

> **NCT02383927** · PHASE2 · COMPLETED · sponsor: **Kura Oncology, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Thyroid Cancer
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- HRAS Mutant Tumor
- Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

## Interventions

- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT02383927
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-13
- **Primary completion:** 2020-12-14
- **Final completion:** 2020-12-14
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02383927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02383927, "Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02383927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*